Phase 1 Interim Population PK/PD Modeling and Recommended Phase 2 Dose Exploration for IMM-1-104, A Novel Concept Oral Deep Cyclic Inhibitor of MEK

Presented at ACoP, Pheonix, AZ, USA (November 13, 2024)